Tobira Therapeutics, Inc

93 articles about Tobira Therapeutics, Inc

• 

  Is the Smoldering NASH Market Ready to Burst Into Flames?

  1/22/2019

  Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
• 

  Updated: Mirum Pharmaceuticals Launches With Phase III-Ready Drug From Shire, $120 Million in Fin...

  11/7/2018

  Based in San Diego, Mirum entered into the agreement with Shire for the exclusive global rights to develop and market maralixibat, a Phase II oral inhibitor of the apical sodium-dependent bile acid transporter (ASBT).
• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!
• 

  Pfizer and Novartis Ink Deal to Test Combination Therapies for NASH

  10/29/2018

  NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
• 

  Is NASH Really a $35 Billion Opportunity?

  9/27/2018

  Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
• 

  WindMIL Therapeutics Raises $32.53 Million

  6/18/2018

  WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing.
• 

  Startup Terns Secures Three NASH Assets From Eli Lilly

  4/4/2018

  The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.

• Allergan Successfully Completes Tobira Acquisition

  11/1/2016

• Turns Out Gilead May Have Wanted Tobira Too

  10/20/2016

• Tobira Announces Late-Breaking Oral Presentation Of CENTAUR Phase IIb Trial Results At The American Academy For The Study Of Liver Diseases Annual Meeting

  10/20/2016

• Allergan And Tobira Announce Early Termination Of Hart-Scott-Rodino Waiting Period For Allergan's Proposed Acquisition Of Tobira

  10/19/2016

• A Look at Allergan's Courtship of Bay Area's Tobira

  10/5/2016

• Tobira Announces Presentations Related To Cenicriviroc’s Development Program In NASH At The American Association for Study of Liver Diseases Annual Meeting

  10/3/2016

• Continuing Its String of Deals, Allergan Buys Bay Area’s Tobira for $1.695 Billion

  9/21/2016

• Tobira Announces Initiation Of Phase I Combination Study of Cenicriviroc And Evogliptin

  9/12/2016

• Tobira Announces Appointment Of Dr. Laurent Fischer As Industry Co-Chair Of The Liver Forum Steering Committee

  9/7/2016

• Tobira To Participate In Two Conferences In September

  9/2/2016

• Tobira Reports Second Quarter 2016 Financial And Business Results

  8/10/2016

• Tobira To Present At The 36th Annual Canaccord Genuity Growth Conference

  8/2/2016

• Tobira To Host Conference Call At 8:30 A.M. Eastern Time Tomorrow To Discuss CENTAUR Phase 2b Trial Results

  7/25/2016